Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors.

Kathleen N. Moore; Joseph Ponte; Patricia LoRusso; Michael J. Birrer; Todd Michael Bauer; Hossein Borghaei; David M. O'Malley; Rodrigo Ruiz-Soto; Robert Lutz; Laeeq Malik

doi:10.1200/jco.2014.32.15_suppl.5571

Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5571 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5571-5571 ◽

Cited By ~ 4

Author(s):

Kathleen N. Moore ◽

Joseph Ponte ◽

Patricia LoRusso ◽

Michael J. Birrer ◽

Todd Michael Bauer ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Solid Tumors ◽

Folate Receptor ◽

Clinical Activity ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Drug Conjugate ◽

Relationship Of ◽

Antibody Drug

Download Full-text

Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5558 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5558-5558 ◽

Cited By ~ 8

Author(s):

Hossein Borghaei ◽

David M. O'Malley ◽

Shelly Marie Seward ◽

Todd Michael Bauer ◽

Raymond P. Perez ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Solid Tumors ◽

Folate Receptor ◽

Phase 1 ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Abstract C47: Association of folate receptor alpha (FRα) expression level and clinical activity of IMGN853 (mirvetuximab soravtansine), a FRα-targeting antibody-drug conjugate (ADC), in FRα -expressing platinum-resistant epithelial ovarian cancer (EOC) patients (pts)

10.1158/1535-7163.targ-15-c47 ◽

2015 ◽

Cited By ~ 2

Author(s):

Lainie P. Martin ◽

Kathleen Moore ◽

David M. O'Malley ◽

Shelley Seward ◽

Todd M. Bauer ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Folate Receptor ◽

Expression Level ◽

Clinical Activity ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Antibody Drug

Download Full-text

Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.04.085 ◽

2018 ◽

Vol 149 ◽

pp. 38 ◽

Cited By ~ 10

Author(s):

U.A. Matulonis ◽

K.N. Moore ◽

L.P. Martin ◽

I.B. Vergote ◽

C.M. Castro ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Phase Ib ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Antibody Drug

Download Full-text

Abstract CT125: STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers

10.1158/1538-7445.am2020-ct125 ◽

2020 ◽

Author(s):

R. Wendel Naumann ◽

Denise Uyar ◽

John W. Moroney ◽

Fadi S. Braiteh ◽

Russell J. Schilder ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Fallopian Tube ◽

Folate Receptor ◽

Phase 1 ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5518 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5518-5518 ◽

Cited By ~ 5

Author(s):

Kathleen N. Moore ◽

Lainie P. Martin ◽

Shelly Marie Seward ◽

Todd Michael Bauer ◽

David M. O'Malley ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Epithelial Ovarian Cancer ◽

Phase I Trial ◽

Folate Receptor ◽

Single Agent ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC)

10.1136/ijgc-2020-igcs.119 ◽

2020 ◽

Author(s):

R Naumann ◽

F Braiteh ◽

J Diaz ◽

E Hamilton ◽

S Diab ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Dose Escalation ◽

Folate Receptor ◽

Phase 1 ◽

Antibody Drug Conjugate ◽

Dose Escalation Study ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.08.015 ◽

2017 ◽

Vol 147 (2) ◽

pp. 402-407 ◽

Cited By ~ 24

Author(s):

Lainie P. Martin ◽

Jason A. Konner ◽

Kathleen N. Moore ◽

Shelly M. Seward ◽

Ursula A. Matulonis ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Epithelial Ovarian Cancer ◽

Cancer Patients ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.5567 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5567-5567 ◽

Cited By ~ 2

Author(s):

Kathleen N. Moore ◽

Lainie P. Martin ◽

Ursula A. Matulonis ◽

Jason A. Konner ◽

Shelly Marie Seward ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Folate Receptor ◽

Single Agent ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Antibody Drug

Download Full-text

FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

Annals of Oncology ◽

10.1093/annonc/mdz250 ◽

2019 ◽

Vol 30 ◽

pp. v403 ◽

Cited By ~ 8

Author(s):

K. Moore ◽

A. Oza ◽

N. Colombo ◽

A. Oaknin ◽

G. Scambia ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Phase Iii ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Phase Iii Study ◽

Antibody Drug

Download Full-text

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Neoplasia ◽

10.1016/j.neo.2016.11.002 ◽

2016 ◽

Vol 18 (12) ◽

pp. 775-784 ◽

Cited By ~ 29

Author(s):

Jose F. Ponte ◽

Olga Ab ◽

Leanne Lanieri ◽

Jenny Lee ◽

Jennifer Coccia ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Standard Of Care ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Cancer Models ◽

Antibody Drug

Download Full-text